DAIRY INDUSTRY BGH COVERUP - Part Two continued from page one
Reproductive and Health Problems under another name?
It is not likely that Eli Lilly would have bought Monsanto’s “big loser” unless they had a rock solid plan for rehabilitating its reputation. Since they are a drug company they may reformulate and rename posilac and we can not expect to get any news about this from mainstream media, as we learned in the Fox News case.
How to avoid the bovine growth hormone, alias rBGH?
In 1994 Monsanto and the FDA maintained that there was no difference in milk from treated and untreated cows, but in 2010 a court challenge proved otherwise. In International Dairy Foods Association v Boggs, it was decided that BGH-free milk is indeed different than milk that comes from cows treated with the Bovine Growth Hormone. This paves the way for milk from untreated cows to be labeled bovine growth hormone-free.
Although it took a lawsuit to force the FDA to allow simple but vital consumer information labeling, according to Organic Consumers.Org, over half of the USA’s largest dairies have completely or partially discontinued use of rBGH. Dean Foods, Starbucks, and Chipotle Mexican Grill have gone completely rBGH-free, as have a few other retailers such as Walmart and Kroger store brand milk. Sam’s Club has pledged to carry only milk from suppliers of un-treated cows.
Your best protection at the grocery store is the knowledge that Organic dairy is BGH-free and trusting those retailers that pledged to carry hormone-free dairy. Thank them next time you shop there, or send email. Wise consumption of dairy products may mean an all-out boycott of products from treated cows but we must keep up the pressure.
The prepared food industry often incorporates dairy ingredients into their products so we must also pressure them to pledge that they will use only bovine growth hormone-free dairy ingredients. Let food producers know you will not purchase dairy products, packaged foods containing dairy ingredients, or pet foods unless they bear a BGH-free statement on the label.
We are surveying Pet Food Companies and will provide that information but in the meantime you should email or call pet food manufacturers and demand assurance that the food does not contain bovine growth hormone in any form. Tell their marketing department that we want to see a BGH-free statement on pet food labels. Remember, it was finally decided by a court of law that “bovine growth hormone-free” is allowed to be stated on the label but it is not currently a requirement.
Take action to protect your dogs and cats from this hormone and don’t forget that it could be in your own diet.
We believe the following information to be accurate but we do not guarantee validity. We advise readers do their own research to establish label authenticity. We do however consider any warning better than NO LABEL WARNING.
Furthermore, we would urge every “animal rights” and animal welfare group to vigorously protest what appears to be extreme, unrelenting cruelty to helpless animals. Read this, then ask the USDA and the FDA why milk from treated cows is allowed to be sold without a warning label???
Someone from UC Davis recently posted, on an agriculture discussion list, the text of the warning label that Monsanto is required to include as an insert with each sale of its version of BST (brand-name: Posilac).
POSILAC (sterile sometribove zinc suspension)
Description: POSILAC (sterile sometribove zinc suspension) is a sterile prolonged-release injectable formulation of a recombinant DNA-derived bovine somatotropin analogue in single-dose syringes each containing 500 mg of sometribove zinc.
Indications For Use: POSILAC is for use in healthy lactating dairy cows to increase production of marketable milk.
Dosage: Inject one syringe of POSILAC every 14 days beginning during the 9th week after calving and continuing until the end of lactation.
Administration: Allow syringes to warm to room temperature (15 to 30C; 59 to 86F) before use. Inject POSILAC subcutaneously (under the skin) in the postcapular region (behind the shoulder) or in the depression on either side of the tailhead (see diagrams below). The injection site should be free of surface debris. Attach a needle securely to a syringe and inject entire contents subcutaneously. Do not reuse needles or syringes.
Human Warnings: Avoid prolonged or repeated contact of POSILAC with eyes and skin. POSILAC is a protein. Frequent skin contact with proteins in general may produce an allergic skin reaction in some people. Always wash hands and skin exposed to POSILAC with soap and water after handling. Clothing soiled with the product should be laundered before reuse. Not for human use. Keep out of reach of children.
Precautions and Side Effects: Use in lactating cattle only. Safety to replacement bulls from dairy cows injected with POSILAC has not been established. To minimize injection site blemishes on the carcass at time of slaughter, avoid injections of POSILAC within 2 weeks of expected slaughter.
Nutritional Management. Feed intake increases over several weeks after initiating the use of POSILAC. This increase occurs earlier for first calf heifers than for second lactation or older cows. Use of POSILAC may reduce the amount of body condition that is normally regained during lactation. This effect is more pronounced for second lactation or older cows. Voluntary feed intake may be increased and body condition decreased during both the dry period and subsequent early lactation. Cows should be fed diets formulated to meet or exceed the nutritional requirements recommended by the National Research Council. Milk yield, stage of lactation, and body condition should be considered when making dietary changes. The feeding program should be managed to optimize energy intake and to have cows in appropriate body condition particularly during late lactation and the dry period.
Reproduction: Use of POSILAC (sterile sometribove zinc suspension) may result in reduced pregnancy rates in injected cows and an increase in days open for first calf heifers. Use of POSILAC has also been associated with increases in cystic ovaries and disorders of the uterus during the treatment period. Cows injected with POSILAC may have increased twinning rates. Also, the incidence of retained placenta may be higher following subsequent calving. Use of POSILAC should be preceded by implementation of a comprehensive and
ongoing herd reproductive health program.
Mastitis: Cows injected with POSILAC are at an increased risk for clinical mastitis (visibly abnormal milk). The number of cows affected with clinical mastitis and the number of cases per cow may increase. In addition, the risk of subclinical mastitis (milk not visibly abnormal) is increased. In some herds, use of POSILAC has been associated with increases in somatic cell counts. Mastitis management practices should be thoroughly evaluated prior to initiating use of POSILAC.
General Health: Use of POSILAC is associated with increased frequency of use of medication in cows for mastitis and other health problems. Cows injected with POSILAC may experience periods of increased body temperature unrelated to illness. To minimize this effect, take appropriate measures during periods of high environmental temperature to reduce heat stress. Care should be taken to differentiate increased body temperature due to use of POSILAC from an increased body temperature that may occur due to illness. Use of POSILAC may result in an increase in digestive disorders such as indigestion, bloat, and diarrhea. There may be an increase in the number of cows experiencing periods of "off-feed" (reduced feed intake) during use of POSILAC. Studies indicated that cows injected with POSILAC had increased numbers of enlarged hocks and lesions (e.g. lacerations, enlargements, calluses) of the knee (carpal region), and second lactation or older cows had more disorders of the foot region. However, results of these studies did not indicate that use of POSILAC increased lameness.
Injection Site Reactions: A mild transient swelling of 3-5 cm (1-2 inches) in diameter may occur at the injection site beginning about 3 days after injection and may persist up to 6 weeks following injection. Some cows may experience swellings up to 10 cm (4 inches) in diameter that remain permanent but are not associated with animal health problems. However, if permanent blemishes are objectionable to the user, administration of the product to the particular animal should be discontinued. Use of POSILAC in cows in which injection site swellings repeatedly open and drain should be discontinued.
Additional Veterinary Information: Care should be taken to differentiate increased body temperature due to use of POSILAC from an increased body temperature that may occur due to illness. Use of POSILAC has been associated with reductions in hemoglobin and hematocrit values during treatment.
Additional Information: Milk production response during each 14-day injection period is cyclic and will be greatest during the middle of each period. No milk discard or preslaughter withdrawal period is required.
Storage: Store under refrigeration (2 to 8C; 36 to 46F.) DO NOT FREEZE. Avoid prolonged exposure to excessively high temperature and sunlight to prevent a decrease in product activity. Expiration dates are stated on syringe and carton labeling.
Environmental Safety: Used syringes and needles should be placed in a leak-resistant, puncture-resistant container for disposal in accordance with applicable Federal, state, and local regulations.
How Supplied: Single-dose syringes in 25-pack cartons. NADA # 140-872, Approved by FDA
Manufactured and packaged for ANIMAL SCIENCES DIVISION OF MONSANTO COMPANY
ST. LOUIS, MISSOURI 63167, U.S.A. Made in Austria